Annals

Neuroprotective Agents (3)

Edited by Edited by William Slikker, Jr. (National Center for Toxicological Research, FDA, Jefferson, Arkansas), Russell J. Andrews (NASA Ames Research Center, Moffet Field, California), and Bruce Trembly (Veterans Affairs Medical Center, Togus, Maine)
Explore the Table of Contents
Neuroprotective Agents (3)

Published: September 2005

Volume 1053

Learn More

As life expectancy has increased, so has the incidence of neurodegenerative diseases, particularly those associated with aging. Contributing to increased life expectancy is increased survival following brain injury, stroke, and procedures such as heart surgery, but these events can impair neurological function. The wide range of contributions to this volume, from a detailed paper on the use of gene therapy in combination with hypothermia for the treatment of cerebral ischemia to a comprehensive poster describing the role of anesthetic agents in neurotoxicity during development and senescence, illustrate the scientific scope presented. Contributions from clinical and basic science researchers from many disciplines address various approaches to providing neuroprotection. The clinical focus is on the complexity of neuroprotection, the need for understanding the time-course effects of hypoxia/ischemia, and the need for combinational and time-course applications of multiple therapies. New technologies are introduced for describing both the insult and the treatment necessary for neuroprotection, including gene expression assays (genomics) and gene therapy.